Licart
Drug
IBSA Pharma Inc.
Total Payments
$357,420
Transactions
6,323
Doctors
3,237
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $44,938 | 169 | 135 |
| 2023 | $130,173 | 202 | 156 |
| 2022 | $36,068 | 837 | 593 |
| 2021 | $121,632 | 4,705 | 2,575 |
| 2020 | $24,608 | 410 | 394 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $141,781 | 6,173 | 39.7% |
| Unspecified | $124,866 | 20 | 34.9% |
| Consulting Fee | $83,263 | 107 | 23.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,100 | 12 | 1.7% |
| Travel and Lodging | $1,409 | 11 | 0.4% |
Payments by Type
General
$232,553
6,303 transactions
Research
$124,866
20 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 18US-FHp04/A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries | IBSA Institut Biochimique SA | $77,723 | 0 |
| Efficacy and Safety of LICART ( diclofenac epolamine), DHEP) Topical System in the Emergency Department: A prospective Observational Study | IBSA Pharma Inc. | $31,175 | 0 |
| Efficacy and Safety of Licart (Diclofenac Epolamine, DHEP) Topical System 1.3% in Patients with Acute Back Pain: A Prospective Observational Study | IBSA Pharma Inc. | $9,853 | 0 |
| Efficacy and Safety of LICART (diclofenac epolamine, DHEP) Topical System in the Emergency Department: A Prospective Observational Study | IBSA Pharma Inc. | $6,115 | 0 |
Top Doctors Receiving Payments for Licart — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Family Medicine | Los Angeles, CA | $352.48 | 10 |
| Olga Colac | Family | Atlanta, GA | $337.51 | 31 |
| , M.D | Internal Medicine | Los Angeles, CA | $322.36 | 32 |
| , M.D.,PH.D | Family Medicine | Alhambra, CA | $307.28 | 5 |
| , PA-C | Physician Assistant | Anaheim, CA | $293.09 | 10 |
| , M.D | Family Medicine | Cerritos, CA | $288.11 | 17 |
| , MD | Family Medicine | Brooklyn, NY | $283.89 | 9 |
| , MD | Physical Medicine & Rehabilitation | Duluth, GA | $272.22 | 25 |
| , M.D | Gastroenterology | Cerritos, CA | $269.63 | 16 |
| , D.O | Internal Medicine | Flushing, NY | $267.90 | 3 |
| , NP | Adult Health | Brooklyn, NY | $262.80 | 9 |
| Steven Kong | Physician Assistant | Brooklyn, NY | $261.67 | 3 |
| , MD | Physical Medicine & Rehabilitation | Hermitage, TN | $258.55 | 12 |
| , M.D | Family Medicine | Brooklyn, NY | $257.73 | 8 |
| Yelena Badalova | — | Los Angeles, CA | $251.51 | 10 |
| , D.O | Rheumatology | West Hollywood, CA | $250.92 | 14 |
| , DPM | Foot & Ankle Surgery | Woodhaven, NY | $250.00 | 2 |
| , PA-C | Surgical | Dayton, OH | $250.00 | 2 |
| , N.P | Family | Montebello, CA | $250.00 | 2 |
| , DO | Family Medicine | Los Angeles, CA | $250.00 | 2 |
| , PA-C | Physician Assistant | Alhambra, CA | $250.00 | 2 |
| , M.D | Physical Medicine & Rehabilitation | Las Vegas, NV | $249.44 | 2 |
| , N.P | Family | Mission Hills, CA | $245.30 | 2 |
| , MD | Specialist | Liverpool, NY | $244.85 | 2 |
| , M.D | Nephrology | Los Angeles, CA | $244.16 | 13 |
Ad
Manufacturing Companies
- IBSA Pharma Inc. $275,959
- IBSA Institut Biochimique SA $81,461
Product Information
- Type Drug
- Total Payments $357,420
- Total Doctors 3,237
- Transactions 6,323
About Licart
Licart is a drug associated with $357,420 in payments to 3,237 healthcare providers, recorded across 6,323 transactions in the CMS Open Payments database. The primary manufacturer is IBSA Pharma Inc..
Payment data is available from 2020 to 2024. In 2024, $44,938 was paid across 169 transactions to 135 doctors.
The most common payment nature for Licart is "Food and Beverage" ($141,781, 39.7% of total).
Licart is associated with 4 research studies, including "18US-FHp04/A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries" ($77,723).